Search
Dallas, TX Paid Clinical Trials
A listing of 1498 clinical trials in Dallas, TX actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1417 - 1428 of 1498
There are currently 1498 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Crohn's Disease Clinical Study
Recruiting
Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.
Conditions:
Crohn's Disease
Crohn Disease
Crohns Disease
Crohn's Disease (CD)
Crohn Colitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depressive disorder Clinical Study
Recruiting
A clinical study for people that suffer with Depressive disorder
Conditions:
Depressive disorder
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Dallas, Texas
Conditions: Neoplasms
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Recruiting
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Mary Crowley Center, Dallas, Texas
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Renal Cell Cancer Metastatic, Renal Cell Carcinoma, Prostate Cancer
SegwayPD: The Effect of Sensory-augmented Postural Training Using Segway on Motor and Cognitive Function in Individuals With Parkinson's Disease
Recruiting
The purpose of this study is to examine the safety and efficacy of postural training emphasized on the integration of multiple sensory information into motor control in individuals with PD. This project is a proof-of-concept study to assess the effectiveness of postural training using Segway, which serves a platform to provide augmented and continuous proprioceptive and visuospatial information during postural training.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
03/13/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Parkinson Disease
LOWER: Lomitapide Observational Worldwide Evaluation Registry
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
ALL
Ages:
All
Trial Updated:
03/11/2024
Locations: Baylor Scott & White Health, Dallas, Texas
Conditions: Homozygous Familial Hypercholesterolemia
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-03-008 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Advanced Solid Tumor
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Recruiting
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Advanced Cancer, Metastatic Cancer
Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study 2.0
Recruiting
Multi-center, prospective, non-randomized study to evaluate outcomes of surgically treated patients with adult cervical spinal deformity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: Medical City Spine Hospital - Southwest Scoliosis Institute, Dallas, Texas
Conditions: Cervical Deformity
Complex Adult Deformity Surgery (CADS)
Recruiting
Evaluate surgical treatment outcomes and identify best practice guidelines for complex adult spinal deformity (ASD) patients, including radiographic and clinical outcomes, surgical and postoperative complications, risk factors for and revision surgery rates, and the role of standard work to improve patient outcomes and reduce surgical and postoperative complications.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: Medical City Spine Hospital - Southwest Scoliosis Institute, Dallas, Texas
Conditions: Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
Recruiting
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/29/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Neurofibromatosis Type 2
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
Recruiting
The investigators' preclinical data have demonstrated the feasibility of fluorescence-guided tumor resection by Cancer Vision Goggles (CVG) with LS301 in animal models. In this study, the investigators will conduct intraoperative imaging procedures that have minimal interference with ongoing surgery. The underlying hypothesis is that the accurate detection of all cancer cells highlighted by LS301 during surgery will reduce the number of breast cancer patients with margin positivity to less than... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Breast Cancer, Cancer of the Breast
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
Recruiting
VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD. KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral vector. The standard of care for patients with neovascular AMD are anti-VEGF treaments, which have demonstrated improvement in vision and reduction in fluid. A one time placement of a product which inhibits VEGF has the potential to reduce the patient burden of regular in... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
02/23/2024
Locations: Kanghong Investigative Site, Dallas, Texas
Conditions: Age-Related Macular Degeneration
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
Recruiting
The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of BMS-986326 via intravenous (IV) infusion or subcutaneous (SC) injection, in participants with different forms of lupus.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/22/2024
Locations: Metroplex Clinical Research Center, Dallas, Texas
Conditions: Lupus
1417 - 1428 of 1498